Evaluating flotetuzumab, a bispecific CD3xCD123 antibody, and magrolimab, a CD47 antibody, together with azacitidine in patients with AML and MDS, respectively, revealed also high remission rates in TP53 aberrant subgroups [41, 42]. This evidence concerns the gene CD47 and acute myeloid leukemia.